In this section, you will learn more about Gattefossé Pharmaceuticals expertise, through news, hot topics and publications at the cutting edge of science, you can browse through a library of on-demands webinars, and download our latest brochures.
Every woman faces a gynecological disorder at some point in her life, during puberty, maternity, menopause or post menopause. These age periods structure the women’s health market with treatments for menopause related disorders, postmenopausal osteoporosis, infertility, endometriosis, gynecological cancer and birth control.
Pediatric patients have specific needs we have to take into account when developing formulations:
- need for dose flexibility to adapt to the body weight
- difficulty to swallow pills
- very sensitive to bitterness
- delicate skin
Focus on some solutions adapted to these specific challenges.
Cannabinoids are challenging drugs to formulate
Self-emulsifying drug delivery systems (SEDDS): In vivo-proof of concept for oral delivery of insulin glargine
In this study, lipophilicity of insulin glargine (IG) was successfully increased via hydrophobic ion pairing (HIP) with sodium octadecyl sulfate to enable incorporation into self-emulsifying drug delivery systems (SEDDS). The SEDDS formulations F1 and F2 were administered to rats via oral gavage and resulted in a bioavailability of 0.55% and 0.44%, corresponding to a 7.7-fold and 6.2-fold increased bioavailability, respectively. Thus, incorporation of complexed insulin glargine into SEDDS formulations provides a promising approach to facilitate its oral absorption.
Learn how to use this self-emulsifying excipient to increase oral drug bioavailability